Portola Pharma (NASDAQ: PTLA) received a Hold rating and a $34 price target from Credit Suisse analyst Vamil Divan today. The company’s shares closed on Friday at $28.17, close to its 52-week low of $24.63.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.1% and a 47.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Eli Lilly & Co.
Portola Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $45.60, which is a 61.9% upside from current levels. In a report issued on August 13, Morgan Stanley also maintained a Hold rating on the stock with a $34 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $64.56 and a one-year low of $24.63. Currently, Portola Pharma has an average volume of 1.32M.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PTLA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
